Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP

2. Date of Event Requiring Statement (MM/DD/YYYY) 5/27/2020

3. Issuer Name and Ticker or Trading Symbol

PLURISTEM THERAPEUTICS INC [PSTI]

(Last) (First) (Middle)

24 BODENHIMER STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director ___X___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

TEL AVIV, L3 6200838

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2511311	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock Warrant	4/8/2019	4/8/2024	Common Stock	47143 ⁽¹⁾	$7 ⁽¹⁾	D

Explanation of Responses:
(1)	Reflects the 1-for-10 reverse stock split effected by Pluristem Therapeutics Inc. on July 25, 2019.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP 24 BODENHIMER STREET TEL AVIV, L3 6200838		X

Signatures
Clover Wolf Capital - Limited Partnership By: Clover Wolf Ltd., its General Partner /s/ Adi Wolf, Chief Executive Officer and Managing Member		6/29/2020
^**Signature of Reporting Person		Date